Find Novel Oncology Drugs in Preclinical Development in FRANCE

Lead Product(s): OX401

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.

Lead Product(s): ABD-3001

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Xerys Funds

Deal Size: $9.8 million Upfront Cash: Undisclosed

Deal Type: Funding February 26, 2020

Details:

Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.

Lead Product(s): OX401

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Onxeo is building a strong preclinical data set for OX401, optimized for both PARP inhibition and STING response as well as bypass resistance., as homologous recombination deficiency requirements.

Lead Product(s): SKY01

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: French Tech Seed

Deal Size: $0.8 million Upfront Cash: Undisclosed

Deal Type: Funding January 20, 2020

Details:

These funds will allow the company to accelerate the development of its flagship drug candidate, before launching a new fundraising round that will address clinical trials.

Lead Product(s): BMC121

Therapeutic Area: Oncology